A Prospective Study of Risk Factor Analysis and Treatment Outcomes of Chemotherapy in Cancer Patients
Research Article
DOI:
https://doi.org/10.69613/qsxdcf86Keywords:
Chemotherapy, Cancer, Risk factors, RECIST criteria, Treatment effectiveness, Patient assessmentAbstract
Cancer treatment outcomes are significantly influenced by patient-specific risk factors and chemotherapy regimen effectiveness. A hospital-based prospective study was conducted to evaluate the relationship between various risk factors and chemotherapy treatment outcomes in 150 cancer patients. Patient data was collected using standardized assessment tools including the Barthel Index for physical functioning, Cumulative Illness Rating Scale for comorbidities, Hospital Anxiety and Depression Scale for psychological assessment, and Medical Social Support Survey Scale for social support evaluation. Treatment effectiveness was assessed using Response Evaluation Criteria in Solid Tumors (RECIST). The mean age of patients was 50.57±12.62 years, with females comprising 66.7% of the study population. Reproductive system cancers were predominant (50.66%), followed by digestive system malignancies. Physical functioning analysis revealed 62% of patients were independent in daily activities. Gastrointestinal adverse effects were most common (27.5%), followed by hematological (24.5%) and dermatological complications (21%). Progressive disease was observed in 37.3% of patients, while 35.4% showed stable disease. Significant associations were found between treatment outcomes and age (p=0.027), physical functioning (p=0.0076), comorbidities (p<0.00001), anxiety and depression (p<0.000072), and adverse reactions (p<0.00001). Social support levels did not show significant correlation with treatment outcomes (p=0.918619). The results of this study indicate that early identification and management of modifiable risk factors could improve chemotherapy outcomes and patient care quality.
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Journal of Pharma Insights and Research

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.